Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 187 clinical trials
featured
QUILT -2.023: A phase 2, open-label, randomized study of ALT-803 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for patients with metastatic NSCLC

arm), as first-line treatment for subjects with metastatic NSCLC in which pembrolizumab is indicated for first-line treatment.

  • 2 views
  • 31 Mar, 2021
  • 1 location
featured
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

tyrosine
lung cancer
EGFR
adjuvant chemotherapy
osimertinib
  • 358 views
  • 08 Dec, 2020
  • 4 locations
featured
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

recurrent non-small cell lung cancer
metastatic non-small cell lung cancer
lung cancer
lung metastases
refractory non-small cell lung cancer
  • 0 views
  • 13 Aug, 2021
  • 40 locations
featured
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

  • 344 views
  • 08 Nov, 2020
  • 38 locations
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).

  • 17 views
  • 22 Sep, 2021
  • 18 locations
  • 14 views
  • 22 Sep, 2021
  • 24 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

measurable disease
cancer treatment
EGFR
epidermal growth factor
osimertinib
  • 30 views
  • 22 Sep, 2021
  • 342 locations
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)

docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti- programmed cell death 1 (PD-1

  • 3 views
  • 24 Sep, 2021
  • 53 locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and

measurable disease
ct scan
progressive disease
pd-l1
docetaxel
  • 151 views
  • 24 Sep, 2021
  • 151 locations
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to …

pemetrexed
EGFR
osimertinib
gilbert's syndrome
neutrophil count
  • 0 views
  • 31 Aug, 2021
  • 11 locations